News about HeRO
We are excited from a tremendous show at #ArabHealth2020 in Dubai. We want to thank @VEDPVirginia for the support and the opportunity to present as a part of the Virginia stand.
ArabHealth is always a great conference to meet with customers, friends, and partners in the Gulf region. We look forward to lots of opportunities and new business.
HeRO has been shown to improve outcomes in another publication in #JPeds, https://www.sciencedirect.com/science/article/abs/pii/S0022347619317457.
This publication adds to the ever growing list of publications supporting the use of HeRO for infants in the NICU.
Medical Predictive Science Corporation, MPSC, has completed the move of its headquarters to a new location. “Our relocation will continue to allow for further growth of the company and the additional headcount needed to support it,” said Will King, CEO.
Please take note of our new address, effective immediately:
Medical Predictive Science Corp.
1233 Cedars Ct, Ste 201
Charlottesville, VA 22901
May 20, 2019 – MPSC welcomes CEMSA to our partners representing HeRO in the many and growing number of countries where HeRO is available. We are delighted to have CEMSA as our representative for Mexico.
CEMSA is working hard to obtain the necessary clearances for the sale of HeRO into Mexico and hopes to be able to launch HeRO soon.
MPSC is proud to continue supporting the NICU Leadership Forum put on by Synova Associates. At this year’s conference in Litchfield, AZ, we had a great time getting to talk with customers, future customers, and all the other wonderful people at the meeting.
We are delighted to congratulate Warren Furry for the winning entry in the raffle.
MPSC is proud to announce that we will be exhibiting at the Arab Health 2019 conference in Dubai, UAE. Arab Health is the largest medical conference in the Middle East.
MPSC will be displaying their HeRO solution as a part of the Virginia Economic Development Partnership (VEDP) stand. “We have been very fortunate to have the support of the VEDP in our efforts to expand our international presence,” said Geoffrey R Alms, PhD, Executive Vice President of MPSC.
HeRO has recently been adopted by Sidra Hospital in Doha, Qatar, and King Hamad Hospital in Al Sayh, Bahrain. “We look forward to working with our partners and leading hospitals in the region,” said Will King, CEO.
May 18th, 2018, Charlottesville, Virginia – HeRO solo and HeRO duet now offer data export.
In an update to the HeRO solo/duet platform, MPSC is proud to announce the availability of data export from the system. “This is in direct response to the voice of our customers,” says Dr. Geoffrey Alms, Executive Vice President of Sales and Marketing at MPSC, “All feedback from our customers is evaluated in trying to improve upon our product portfolio.”
The new option, called “USB Data Export,” will be offered as an optional upgrade available immediately on new production units of HeRO solo and HeRO duet. With the option, customers can export the data from the HeRO monitor onto a user supplied USB stick as a text file. This solution was developed in order to allow clinicians, who are interested in doing research incorporating HeRO, a mechanism for collecting the digital data generated by HeRO.
Please contact your local representative about the availability of all the HeRO Products.
May 14th, 2018, Charlottesville, Virginia – the Journal Pediatrics has just published two articles about HeRO monitoring.
In the first, “Predicting Extubation Outcomes-A Model Incorporating Heart Rate Characteristics Index”, authors Goel, Chakraborty, Watkins, and Banerjee examined HRC as a predictor of extubation outcome in neonatal patients. They found that patients that failed extubations had both higher baseline HeRO Scores as well as higher post-extubation changes in HRC Scores than infants that succeeded extubation.
In the second, “Neonatal Intensive Care Unit Length of Stay Reduction by Heart Rate Characteristics Monitoring”, Swanson and co-authors examined length of stay differences between the two arms of the HeRO randomized controlled trial in light of the competing outcome of a mortality benefit. They found HeRO monitored patients to be discharged alive and before the 120th day of life at a higher rate than controls (83.6% versus 80.1%, p=0.01). They also found that among surviving patients with a positive blood culture, HeRO monitored patients were discharged at a 3.2 day lower PMA than controls (p=0.03).
“Clinicians face a real challenge in choosing when to extubate a ventilated patient,” commented Dr. Geoffrey Alms, Executive Vice President of Sales and Marketing at MPSC. “Leaving the patient ventilate increases the risk of pneumonia, but pulling the tube out before the patient is ready, resulting in re-intubation, results in its own set of morbidities. Any role that HeRO can play in helping the clinicians choose the right time to extubate will greatly benefit patients.”
Turning to the length of stay publication, Alms commented, “Length of stay in the NICU is a surrogate for cost. So, reducing length of stay is not only good for patients and families, but good for hospitals as well.” He added, “The more we study HeRO monitoring, the more we learn about its benefits.”
MPSC is proud to have played a part in the care of the Waldrop sextuplets in Huntsville, Alabama. “When we heard that Huntsville Hospital was about to have sextuplets join them, we knew we had to help,” says Geoff Alms, Executive Vice President. “Within a week of learning about the pending arrival, we were able to deliver 6 new HeRO Solos ready for use.”
Charlottesville, VA. As MPSC continues to improve the HeRO product portfolio, we are proud to announce that MPSC has received a substantially equivalent notification regarding its most recent 510k submission, the summary of which is available at https://www.accessdata.fda.gov/cdrh_docs/pdf18/K180242.pdf.
November 29, 2017 – MPSC wants to thank the Virginia Economic Development Partnership (@YesVirginia_org) for the opportunity to exhibit as a proud Virginia based company.
“Medica is a key congress to explore business opportunities throughout the world,” said Geoffrey Alms, Executive Vice President. “We enjoyed meeting with our current and future partners to bring HeRO to more NICU patients. Medica has been an important part of the expansion of HeRO into many new markets.”
Charlottesville, VA– June 20th, 2017 MPSC announced today that it signed the Patient Safety Movement’s Open Data Pledge, a public pledge to share its data to promote patient safety.
The Open Data Pledge is designed to foster a marketplace of data analytics to encourage entrepreneurs to develop novel uses of health data that will improve patient safety and reduce preventable deaths. If enough medical technology companies share the data their products generate, it allows engineers and researchers to develop predictive algorithms that notify clinicians and patients of dangerous trends, such as MPSC’s HeRO product. The pledge does not ask any company to share protected or proprietary data or not follow all the privacy laws. To date, 80 companies have made the pledge: http://patientsafetymovement.org/commitments/medical-technology-company-pledges.
“Our HeRO Product line proves that the idea of sharing data among device makers and entrepreneurs results in saved lives,” said Will King, CEO. “We look forward to working closely with the Patient Safety Movement Foundation to further the goal of eliminating preventable patient deaths.”
More than 3,000,000 people worldwide, and 200,000+ people in the United States die every year in hospitals in ways that could have been prevented. It is the 3rd leading cause of death in the US and the cost is close to $1.44 Trillion. If every Very Low Birth Weight baby in the US were monitored by HeRO, 1,200 additional lives could be saved while simultaneously reducing costs and length of stay. The Patient Safety Movement Foundation is a non-profit that is working with all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. Their mission and public commitment is to eliminate preventable patient deaths by the year 2020. Their annual World Patient Safety, Science and Technology summit presents specific, actionable solutions to meet patient safety challenges and highlights the hospitals’ commitments to implement Actionable Patient Safety Solutions and medical technology companies that have pledged to share data.
Medical Predictive Science Corporation is engaged in the development of computational diagnostic and bio-informatic technologies for the healthcare industry. MPSC is committed to saving lives and reducing healthcare expenditures through the development of effective clinical diagnostic and decision support tools. These products use computational diagnostic methods to make the early diagnosis of clinical illness through continuous, non-invasive patient monitoring, and to provide diagnostic information as well as decision support to the physician. HeRO is a trademark of Medical Predictive Science Corporation.
# # #
Twitter: @mpschero #patientsafety
At the recently concluded Pediatric Academics Society Annual Conference in San Francisco, there were multiple abstracts presented about the HeRO System. Please take a look at these new studies:
Sepsis screening in very low birth weight infants using heart rate characteristics monitor. Schibler K, Moreira D.
PAS Conference Abstract (2017).
Reduced NICU Length of Stay Using Heart Rate Characteristics Monitoring. Swanson, JR, King W, Carlo W, Sinkin RA, Schelonka R, Porcelli PJ, Navarrete C, Bancalari E, Aschner JL, Perez J, Palmer C, O’Shea M, Walker W.
PAS Conference Abstract (2017).
Cost Analysis of Heart Rate Characteristics Monitoring in the NICU. Karvonen KL, Vergales J, Sinkin RA, Swanson JR.
PAS Conference Abstract (2017).
MPSC is proud to continue supporting the NICU Leadership Forum put on by Synova Associates. At this year’s conference in Litchfield, AZ, we had a great time getting to talk with customers, future customers, and all the other great nurses at the meeting.
Come see us at the NeoHeart: Cardiovascular Management of the Neonate conference at the Manchester Grand Hyatt, San Diego, CA. At this conference, Will King, CEO of MPSC, will be a member of a panel. We’re delighted to have this opportunity to be a part of this conference.
Welcome to HeRO. Please enjoy this video overview of the HeRO product.
NICU Technology at Timpanogos Regional Hospital
MPSC is delighted to recognize Meditech as the newest distributor for the HeRO System. Meditech, located in Kingston, Jamaica, has placed a HeRO duet unit into the University Hospital of the West Indies. In addition, we will be presenting HeRO at the 15th Caribbean Neurosciences Symposium. This conference is being held in Montego Bay, Jamaica, from the 26th to the 29th of January.
MPSC is proud to continue building upon the HeRO presence in the international markets. HeRO will be shown at booth Z6.F46 as a part of the US International Pavilion at the Arab Health 2017 conference in Dubai. We look forward to meeting with our established distributors and distributors for additional markets to discuss strategy and to explore beneficial opportunities with our partners. Please come and visit us in Za’abeel Hall 6, stand Z6.F46 while attending the conference.
We anticipate a great opportunity to meet with our dealers and prospective dealers at the upcoming MEDICA 2016 conference in Dusseldorf, Germany. This conference is the one place and time when we can meet with dealers for much of the world all at one place.
This year, MPSC will be a part of the USA CEO pavilion in Hall 16, Booth 16C04. We look forward to productive discussions towards expanding the usage of HeRO into new markets, both in Europe and beyond.